Comparative Pharmacology
Head-to-head clinical analysis: ALPHADERM versus CORDRAN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHADERM versus CORDRAN N.
ALPHADERM vs CORDRAN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic